High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70292 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Eric J Lenze und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Fluvoxamine, COVID-19 Drug Treatment, Drug Monitoring. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Clinical trials are increasingly using remote monitoring techniques at the patient's home. We conducted a secondary analysis of remote safety and tolerability monitoring from two fully‐remote clinical trials that tested fluvoxamine for the acute treatment of COVID‐19. Both trials assessed pulse and blood pressure daily, and one study assessed symptoms daily via Ecological Momentary Assessment. On average, patients provided data on vital signs on 93% of the study days and provided data on side effects on 81% of the study days. With respect to safety, patients taking fluvoxamine had reduced pulse rate compared to placebo, with the greatest difference—5 points—at treatment Day 4. In contrast, fluvoxamine showed little to no effect on blood pressure. With respect to tolerability, nausea was most frequent in the first 4–5 days, declining significantly thereafter, while anxiety and difficulty concentrating were uncommon with fluvoxamine compared to placebo. These findings show that remote assessment of safety and tolerability is feasible in clinical trials, and that frequent assessments can provide in‐depth data on the timecourse of safety or tolerability signals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.
ORCID-Profile: Eric J Lenze, Julia Schweiger, Torie Gettinger, Michael Yingling, Yi Zhang, Ginger E Nicol, Charles F Zorumski, Angela M Reiersen
Zitieren
APA
Lenze, E. J., Nykamp, M., Miller, J. P., Stevens, A., Schweiger, J., Gettinger, T., Yingling, M., Zhang, Y., Nicol, G. E., Zorumski, C. F., & Reiersen, A. M. (2025). High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment. Clinical and Translational Science. https://doi.org/10.1111/cts.70292
Vancouver
Lenze EJ, Nykamp M, Miller JP, Stevens A, Schweiger J, Gettinger T, et al. High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment. Clinical and Translational Science. 2025. doi:10.1111/cts.70292
BibTeX
@article{Lenze2025,
author = {Lenze, Eric J and Nykamp, Madeline and Miller, J Philip and Stevens, Angela and Schweiger, Julia and Gettinger, Torie and Yingling, Michael and Zhang, Yi and Nicol, Ginger E and Zorumski, Charles F and Reiersen, Angela M},
title = {High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70292}
}
EUVIMED